The linker matters in antibody-drug conjugates Interviewee/Contributor Philipp Spycher Organisation Araris Biotech AG Antibody Drug Conjugates ADCs Cancer (Oncology) Drug discovery Read more about The linker matters in antibody-drug conjugates
The US continues to lead in oncology approvals Interviewee/Contributor Bruno Pagliara Organisation MedNous Antibody Drug Conjugates ADCs Cancer (Oncology) Clinical trials Immunotherapy Policy & Regulation Read more about The US continues to lead in oncology approvals
Revisiting antibody-drug conjugates Interviewee/Contributor Chris Martin Organisation ADC Therapeutics SA Antibody Drug Conjugates ADCs Drug discovery Strategy Read more about Revisiting antibody-drug conjugates
Targeting new medicines at Roche Interviewee/Contributor Max Hasmann Organisation Roche Group Antibody Drug Conjugates ADCs Cancer (Oncology) Personalised medicine Breast cancer Read more about Targeting new medicines at Roche
The inventive step: antibody-drug conjugates Interviewee/Contributor John Lambert Organisation ImmunoGen Inc Cancer (Oncology) Antibody Drug Conjugates ADCs Read more about The inventive step: antibody-drug conjugates
Antibodies and ADCs lead cancer pipeline Interviewee/Contributor Bruno Pagliara Organisation On-Kos Pharma Consulting Antibody Antibody Drug Conjugates ADCs Cancer (Oncology) Read more about Antibodies and ADCs lead cancer pipeline
ADCs propelled back into the oncology spotlight Interviewee/Contributor Karen Finn Organisation MedNous Antibody Drug Conjugates ADCs Read more about ADCs propelled back into the oncology spotlight
Why Oxford BioTherapeutics is targeting ADCs Interviewee/Contributor Christian Rohlff Organisation Oxford BioTherapeutics Ltd Antibody Drug Conjugates ADCs Read more about Why Oxford BioTherapeutics is targeting ADCs
How developers approach antibody drug conjugates Interviewee/Contributor Bruno Pagliara Organisation On-kòs Pharma Consulting Cancer (Oncology) Antibody Drug Conjugates ADCs Hodkin's Lymphoma Read more about How developers approach antibody drug conjugates